FIELD: biochemistry.
SUBSTANCE: invention relates to an isolated humanized anti-transferrin receptor (TfR) antibody or anti-TfR humanized antibody antigen-binding fragment, a method for preparing it, as well as to an immunoconjugate, a pharmaceutical composition and a lyophilized preparation containing said antibody. Also disclosed is a vector comprising at least one nucleic acid coding said TfR antibody, as well as disclosed is a host cell containing said vector. Invention also relates to a method of detecting transferrin receptor in a sample involving contact of a sample with said antibody.
EFFECT: invention enables effective tumor treatment in a subject.
17 cl, 9 tbl, 5 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY-DRUG CONJUGATES AND THEIR USE FOR THE TREATMENT OF CANCER DISEASES | 2019 |
|
RU2799547C2 |
| AGENT FOR INHIBITING IRON ABSORPTION BY CELLS | 2019 |
|
RU2817146C2 |
| BISPECIFIC ANTIBODIES BINDING TO TFR | 2019 |
|
RU2810756C2 |
| ANTIBODIES AGAINST TRANSFERRIN RECEPTOR HAVING INDIVIDUALIZED AFFINITY | 2016 |
|
RU2729416C2 |
| ANTI-TRANSFERRIN RECEPTOR ANTIBODIES WITH INDIVIDUALIZED AFFINITY | 2016 |
|
RU2831724C2 |
| ANTIBODY CAPABLE OF BINDING TO THYMIC STROMAL LYMPHOPOIETIN, AND USE THEREOF | 2020 |
|
RU2825304C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF MALIGNANT TUMOR | 2017 |
|
RU2766586C2 |
| TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
| ANTI-CLDN-18.2 ANTIBODY AND USE THEREOF | 2021 |
|
RU2829997C1 |
| ANTIBODY AGAINST SIRPα | 2019 |
|
RU2791002C2 |
